NO20004271L - Benzylpiperazinyl- og benzylpiperidinyletanonderivater, deres fremstilling og deres anvendelse som dopamin D4- reseptorantagonister - Google Patents
Benzylpiperazinyl- og benzylpiperidinyletanonderivater, deres fremstilling og deres anvendelse som dopamin D4- reseptorantagonisterInfo
- Publication number
- NO20004271L NO20004271L NO20004271A NO20004271A NO20004271L NO 20004271 L NO20004271 L NO 20004271L NO 20004271 A NO20004271 A NO 20004271A NO 20004271 A NO20004271 A NO 20004271A NO 20004271 L NO20004271 L NO 20004271L
- Authority
- NO
- Norway
- Prior art keywords
- alkyl
- represents hydrogen
- rog
- benzylpiperidinylethanone
- benzylpiperazinyl
- Prior art date
Links
- HOJGUDWNFKNCPF-UHFFFAOYSA-N 3-phenyl-1-piperidin-1-ylpropan-1-one Chemical class C1CCCCN1C(=O)CCC1=CC=CC=C1 HOJGUDWNFKNCPF-UHFFFAOYSA-N 0.000 title 1
- -1 Benzylpiperazinyl Chemical group 0.000 title 1
- 229940124243 Dopamine D4 receptor antagonist Drugs 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000007812 deficiency Effects 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 239000011593 sulfur Substances 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 206010026749 Mania Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 231100000867 compulsive behavior Toxicity 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000003557 neuropsychological effect Effects 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/54—Spiro-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- C07D215/08—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms with acylated ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Indole Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Forbindelser med formel (I) eller farmasøytisk akseptable syreaddisjonssalter derav der Y betyr oksygen eller svovel, Z betyr nitrogen eller CH, Ri, Rog Rbetyr hydrogen, halogen, hydroksy, alkoksy, alkyl, trifluormetyl eller trifluormetoksy, Rog Rbetyr hydrogen, alkyl eller danner en ring med det atom hvortil de er bundet, Rbetyr hydrogen, alkyl, alkoksy eller alkyltio, og Rbetyr hydrogen eller alkyl, eller Rog Re sammen med atomet hvortil de er bundet danner en ring, og R, R, Rg, Rio og Rn betyr hydrogen eller alkyl.Forbindelsene som beskrevet ovenfor er brukbare ved terapi og/eller prevensjon av neuropsykologiske mangler inkludert schizofreni, mani, demens, depresjon, angst, kompulsiv oppførsel, stoffmisbruk, Parkinson-lignende motormangler og mosjonsmangler relatert bruken av neuroleptiske midler.Videre beskrives mellomprodukter med formlene (VII-a) og (VII-b) der X betyr oksygen eller svovel eller CH, m er null eller et helt tall fra 1-4 og L er en avgangsgruppe.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3098798A | 1998-02-26 | 1998-02-26 | |
| PCT/US1999/004309 WO1999043670A1 (en) | 1998-02-26 | 1999-02-26 | Benzylpiperazinyl- and benzylpiperidinyl ethanone derivatives, their preparation and their use as dopamine d4 receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20004271D0 NO20004271D0 (no) | 2000-08-25 |
| NO20004271L true NO20004271L (no) | 2000-10-25 |
Family
ID=21857045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20004271A NO20004271L (no) | 1998-02-26 | 2000-08-25 | Benzylpiperazinyl- og benzylpiperidinyletanonderivater, deres fremstilling og deres anvendelse som dopamin D4- reseptorantagonister |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1068193A1 (no) |
| JP (1) | JP2002504549A (no) |
| KR (1) | KR20010041341A (no) |
| CN (1) | CN1293669A (no) |
| AU (1) | AU2881499A (no) |
| CA (1) | CA2321830A1 (no) |
| HU (1) | HUP0100926A3 (no) |
| IL (1) | IL137930A0 (no) |
| NO (1) | NO20004271L (no) |
| PL (1) | PL342597A1 (no) |
| WO (1) | WO1999043670A1 (no) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6084098A (en) | 1999-02-26 | 2000-07-04 | Neurogen Corporation | Benzylpiperazinyl and piperidinyl ethanone derivatives: dopamine receptor subtype specific ligands |
| AU5487300A (en) * | 1999-06-14 | 2001-01-02 | Neurogen Corporation | Benzylpiperazinyl-indolinylethanones |
| US6355644B1 (en) | 1999-06-14 | 2002-03-12 | Neurogen Corporation | Benzylpiperazinyl-indolinylethanones |
| EP1177792A3 (en) | 2000-07-27 | 2002-10-23 | Pfizer Products Inc. | Dopamine D4 Ligands for the treatment of novelty-seeking disorders |
| KR100394086B1 (ko) | 2000-12-04 | 2003-08-06 | 한국과학기술연구원 | 도파민 ｄ3 및 ｄ4 수용체의 선택적 활성을 지닌 신규이소옥사졸릴알킬피페라진 유도체와, 이의 제조방법 |
| KR100394083B1 (ko) | 2000-12-04 | 2003-08-06 | 학교법인 성신학원 | 도파민 ｄ3 및 ｄ4 수용체의 선택적 활성을 지닌 신규4,5-디히드로이소옥사졸릴알킬피페라진 유도체와, 이의제조방법 |
| CN1181065C (zh) | 2002-05-08 | 2004-12-22 | 上海医药工业研究院 | 芳烷甲酰烷基哌嗪衍生物及其作为脑神经保护剂的应用 |
| DE102004027358A1 (de) * | 2004-06-04 | 2005-12-29 | Abbott Gmbh & Co. Kg | Pyrimidinverbindungen und ihre Verwendung |
| CA2589363A1 (en) | 2004-12-13 | 2006-06-22 | Eli Lilly And Company | Spiro derivatives as lipoxygenase inhibitors |
| GB201106817D0 (en) * | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compound |
| RU2720237C2 (ru) | 2013-11-18 | 2020-04-28 | Форма Терапеутикс, Инк. | Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет |
| BR122019007990B1 (pt) | 2013-11-18 | 2021-05-04 | Forma Therapeutics, Inc | Composto, e, composição farmacêutica |
| CN115368356B (zh) | 2013-12-20 | 2025-05-09 | 阿斯特克斯治疗有限公司 | 双环杂环化合物及其治疗用途 |
| CN103966340B (zh) * | 2014-05-26 | 2015-09-16 | 宁波大学 | 一种用于辅助诊断阿尔茨海默病的检测试剂盒及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2863752A (en) * | 1953-10-30 | 1958-12-09 | Monsanto Chemicals | Herbicides |
| US2909523A (en) * | 1957-10-11 | 1959-10-20 | American Cyanamid Co | Substituted piperazines and method of preparing the same |
| US3268584A (en) * | 1961-08-28 | 1966-08-23 | Monsanto Co | Herbicidal alpha-haloacetanilides |
| NL128941C (no) * | 1964-02-19 | 1970-06-15 | ||
| DE2604224A1 (de) * | 1976-02-04 | 1977-08-11 | Hoechst Ag | Herbizide mittel |
| JPS5318540A (en) * | 1976-08-02 | 1978-02-20 | Nippon Nohyaku Co Ltd | Alpha-chloroacetamides and their use |
| HU201757B (en) * | 1988-03-11 | 1990-12-28 | Pfizer | Process for producing pyrroloquinoline-, acridine-, benzoxazine-, benzthiazine-, indolobenzoxazine-, benzazepine and pyrrolophenothiazine carboxamides and pharmaceutical compositions comprising same |
| EP0934932A4 (en) * | 1996-08-22 | 2002-06-26 | Meiji Seika Kaisha | CHINOLINE DERIVATIVES AND PSYCHOTROPES MEDIUM |
| ATE287878T1 (de) * | 1996-08-23 | 2005-02-15 | Neurosearch As | Disubstituierte morpholin-, oxazepin- oder thiazepinderivate, deren herstellung und verwendung als dopamin-d4-rezeptorantagonisten |
| AU6256198A (en) * | 1997-02-19 | 1998-09-09 | Hoechst Marion Roussel, Inc. | Benzamides having dopamine d4 receptor affinity |
| WO1999021848A2 (en) * | 1997-10-27 | 1999-05-06 | Neurogen Corporation | Novel 1-(n'-(arylalkylaminoalkyl))aminoisoindoles; a new class of dopamine receptor subtype specific ligands |
| AU1286399A (en) * | 1997-10-31 | 1999-05-24 | Neurogen Corporation | 3-aminoalkylamino- 2h-1,4-benzoxazines and 3-aminoalkylamino- 2h-1,4-benzothiazines: dopamine receptor subtype specific ligands |
-
1999
- 1999-02-26 HU HU0100926A patent/HUP0100926A3/hu unknown
- 1999-02-26 CA CA002321830A patent/CA2321830A1/en not_active Abandoned
- 1999-02-26 AU AU28814/99A patent/AU2881499A/en not_active Abandoned
- 1999-02-26 EP EP99909657A patent/EP1068193A1/en not_active Withdrawn
- 1999-02-26 CN CN99804026A patent/CN1293669A/zh active Pending
- 1999-02-26 PL PL99342597A patent/PL342597A1/xx not_active Application Discontinuation
- 1999-02-26 WO PCT/US1999/004309 patent/WO1999043670A1/en not_active Ceased
- 1999-02-26 KR KR1020007009454A patent/KR20010041341A/ko not_active Withdrawn
- 1999-02-26 JP JP2000533426A patent/JP2002504549A/ja active Pending
- 1999-02-26 IL IL13793099A patent/IL137930A0/xx unknown
-
2000
- 2000-08-25 NO NO20004271A patent/NO20004271L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20004271D0 (no) | 2000-08-25 |
| CN1293669A (zh) | 2001-05-02 |
| AU2881499A (en) | 1999-09-15 |
| PL342597A1 (en) | 2001-06-18 |
| KR20010041341A (ko) | 2001-05-15 |
| HUP0100926A2 (hu) | 2001-09-28 |
| CA2321830A1 (en) | 1999-09-02 |
| IL137930A0 (en) | 2001-10-31 |
| WO1999043670A1 (en) | 1999-09-02 |
| JP2002504549A (ja) | 2002-02-12 |
| HUP0100926A3 (en) | 2003-03-28 |
| EP1068193A1 (en) | 2001-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE366724T1 (de) | Kondensierte heterocyclische derivate | |
| NO20034595D0 (no) | Kinolin- og kinazolinderivater med azolylgruppe | |
| NO20074657L (no) | Nitrogenholdige aromatiske ringforbindelser | |
| MXPA04004982A (es) | Derivados de benzotiazol. | |
| NO20031561L (no) | Kjemiske forbindelser | |
| IL151533A0 (en) | Novel cyclic amide derivatives | |
| NO20060206L (no) | Nye azetidinforbindelser | |
| WO2000018767A3 (en) | 2-piperazino alkylamino benzoazole derivatives: dopamine receptor subtype specific ligands | |
| SG164268A1 (en) | Quinolin-4-yl derivatives i | |
| MXPA05012120A (es) | 2-imidazo-benzotiazoles como ligandos de receptores de adenosina. | |
| HU0103912D0 (en) | Use of substituted alkylpyridazinone derivatives for the preparation of pharmaceutical compositions with anxiolytic activity | |
| WO1999021848A3 (en) | Novel 1-(n'-(arylalkylaminoalkyl))aminoisoindoles; a new class of dopamine receptor subtype specific ligands | |
| DE60130628D1 (de) | Aminophenoxyacetamid derivate und diese enthaltende pharmazeutische zusammensetzungen | |
| NO20033049D0 (no) | Fremgangsmåte for fremstilling av (+/-) trans-4-p-fluorfenyl- 3-hydroksymetyl-1 | |
| MY133207A (en) | Substituted benzolactam compaunds | |
| PT1120415E (pt) | Compostos de isoxazoliltiofeno substituido | |
| WO2005109987A3 (en) | 3-(((4-phenyl)-piperazine-1-yl)-alkyl)-3-alkyl-1, 3-dihydro-2h-indol-2-one derivatives and related compounds for the treatment of central nervous system disorders | |
| DE60227113D1 (de) | Kondensierte camptothecine als antitumormittel | |
| PT1140925E (pt) | 3,4-di-hidro-2h-benzo¬1,4|oxazinil-metil-¬3-(1h-indol-3il)-alquil|-aminas | |
| NO20045124L (no) | Nye piperidinylalkylaminpyridazinonderivater, en fremgangsmate for fremstilling derav og farmasoytiske preparater inneholdende nevnte forbindelser | |
| DE60239324D1 (de) | Phenyl- und pyridyl-piperidine mit tnf-wirkung | |
| WO2001035938A3 (de) | Pharmakologisch aktive tetrahydrothiopyran-4-ol-derivate, verfahren zu ihrer herstellung und verwendung | |
| NO20082254L (no) | Behandling av stressurininkontinens og blandet urininkontinens | |
| WO2000012500A3 (en) | 2-aryl-4-(1-[4-heteroaryl]piperazin-1-yl) methylimidazoles: dopamine d4 receptor subtype ligands | |
| NZ503588A (en) | 2,3,3a,7b-tetrahydro-1H-benzo[3,4]cyclobuta[1,2-c]pyrrole derivatives useful as serotonin reuptake inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |